Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 747 results
Found 747 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

P

Kuritzkes DR, Ribaudo HJ, Squires KE, et al. "Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s." J. Infect. Dis.. 2007;195(8):1169-76.
Sinxadi PZuleika, McIlleron HMargaret, Dave JAlex, et al. "Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations." Medicine (Baltimore). 2016;95(2):e2385.
Bruggeman LA, O'Toole JF, Ross MD, et al. "Plasma apolipoprotein L1 levels do not correlate with CKD." J. Am. Soc. Nephrol.. 2014;25(3):634-44.
Schifitto G, Yiannoutsos CT, Simpson DM, et al. "A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy." J. Neurovirol.. 2006;12(4):328-31.
Wilkin TJ, Lalama CM, McKinnon J, et al. "A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4⁺ T-cell recovery despite sustained virologic suppression: ACTG A5256." J. Infect. Dis.. 2012;206(4):534-42.
Tungsiripat M, Kitch D, Glesby MJ, et al. "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206." AIDS. 2010;24(11):1781-4.
Marks KM, Kitch D, Chung RT, et al. "Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239." J. Acquir. Immune Defic. Syndr.. 2014;65(3):345-9.
Henry K, Katzenstein D, Cherng DWeng, et al. "A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy +/- interleukin 2: results of ACTG A5102." J. Acquir. Immune Defic. Syndr.. 2006;42(2):140-8.
Smith DM, Mathews WChristophe. "Physicians' attitudes toward homosexuality and HIV: survey of a California Medical Society- revisited (PATHH-II)." J Homosex. 2007;52(3-4):1-9.
Chow FC, Makanjuola A, Wu K, et al. "Physical Activity Is Associated With Lower Odds of Cognitive Impairment in Women but Not Men Living With Human Immunodeficiency Virus Infection." J. Infect. Dis.. 2019;219(2):264-274.
Vardhanabhuti S, Taiwo B, Kuritzkes DR, Eron JJ, Bosch RJ. "Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia." Antivir. Ther. (Lond.). 2015;20(1):73-6.
Derache A, Wallis CL, Vardhanabhuti S, Bartlett J, Kumarasamy N, Katzenstein D. "Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection." J. Infect. Dis.. 2016;213(2):250-6.
Verma SS, Frase AT, Verma A, et al. "PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG)." Pac Symp Biocomput. 2016;21:57-68.
Moore CB, Verma A, Pendergrass S, et al. "Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols." Open Forum Infect Dis. 2015;2(1):ofu113.
Para MF, Schouten J, Rosenkranz SL, et al. "Phase I/II trial of the anti-HIV activity of mifepristone in HIV-infected subjects ACTG 5200." J. Acquir. Immune Defic. Syndr.. 2010;53(4):491-5.
Dooley KE, Luetkemeyer AF, Park J-G, et al. "Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin." Antimicrob. Agents Chemother.. 2014;58(9):5245-52.
Sherman KE, Kang M, Sterling R, et al. "Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection." World J Hepatol. 2017;9(4):217-223.
Gulick RM, Wilkin TJ, Chen YQ, et al. "Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)." J. Infect. Dis.. 2017;215(2):238-246.
Gulick RM, Su Z, Flexner C, et al. "Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211." J. Infect. Dis.. 2007;196(2):304-12.
Decloedt EH, van der Walt JS, McIlleron H, Wiesner L, Maartens G. "The pharmacokinetics of lopinavir/ritonavir when given with isoniazid in South African HIV-infected individuals." Int. J. Tuberc. Lung Dis.. 2015;19(10):1194-6.
Gupta SK, Rosenkranz SL, Cramer YS, et al. "The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis." AIDS. 2008;22(15):1919-27.
Crawford KW, Li C, Keung A, et al. "Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211)." J. Acquir. Immune Defic. Syndr.. 2010;53(5):598-605.
Aberg JA, Rosenkranz SL, Fichtenbaum CJ, et al. "Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108." AIDS. 2006;20(5):725-9.
Ma Q, Forrest A, Rosenkranz SL, et al. "Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers." Biopharm Drug Dispos. 2008;29(2):91-101.
Sha BE, Tierney C, Sun X, et al. "PHARMACOKINETIC EXPOSURE AND VIROLOGIC RESPONSE IN HIV-1 INFECTED PREGNANT WOMEN TREATED WITH LOPINAVIR/RITONAVIR: AIDS CLINICAL TRIALS GROUP PROTOCOL A5153S: A SUBSTUDY TO A5150." Jacobs J AIDS HIV. 2015;1(1).
Aweeka FT, Kang M, Yu J-Y, Lizak P, Alston B, Chung RT. "Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team." HIV Med.. 2007;8(5):288-94.
Castillo-Mancilla JR, Aquilante CL, Wempe MF, et al. "Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342)." J. Antimicrob. Chemother.. 2016;71(6):1609-18.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
Haas DW, Bartlett JA, Andersen JW, et al. "Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration." Clin. Infect. Dis.. 2006;43(6):783-6.
Wu H, Huang Y, Acosta EP, et al. "Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence." J Pharmacokinet Pharmacodyn. 2006;33(4):399-419.

Pages